Recent Posts
- OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
- Video Transcript: Risk-Based Care: Personalized care for better patient outcomes
- Video Transcript: Risk-Based Care: Personalized care for better outcomes | Dan & Porscha
- VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
- Improving Oncology Patient Outcomes: The Future of Risk-Based Care